Dynamic Susceptibility Contrast Magnetic Resonance Imaging with Carbon-Encapsulated Iron Nanoparticles Navigated to Integrin Alfa V Beta 3 Receptors in Rat Glioma.

Overexpression of αvβ3 integrin is found in a diverse group of tumors originating from glial cells in the brain, making this transmembrane receptor a promising biomarker for molecular MRI diagnosis. In the study, we conjugated a monoclonal antibody against the β3 subunit (CD61) of the αvβ3 integrin receptor with carbon-encapsulated iron nanoparticles to yield Fe@C-(CH)-CONH-anti-CD61 bioconjugates that were used in dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI). Wistar rats bearing C6 gliomas were injected as a single bolus (0.5 mL) through the tail vain with a suspension of Fe@C-(CH)-CONH-anti-CD61 nanoparticles (200 μg mL) and the animals were imaged using the T2*-weighted echo planar imaging (T2* EPI) technique. Results showed that intravenously infused nanoparticles targeting αvβ3 integrin receptors provide strong contrast in rat glioma tissues. No such effects were observed in other rat organs, although some post-contrast effects were also noted in the liver and kidney. The study shows that the as-developed nanoparticles decorated with anti-CD61 monoclonal antibodies might be considered as a novel contrast candidate for noninvasive DSC-MRI diagnosis in CD61-positive gliomas.